Results 1 to 10 of about 12,165 (179)

Can Patients with Hematologic Disease and Prior Mucormycosis Undergo Stem Cell Transplantation? [PDF]

open access: yesJournal of Fungi
The prognosis of mucormycosis after hematopoietic stem cell transplantation (HSCT) is generally poor but data on post-HSCT outcomes in patients with pre-HSCT mucormycosis are limited.
Armando Leon   +5 more
doaj   +2 more sources

Disease Entities in Mucormycosis

open access: yesJournal of Fungi (Basel, Switzerland), 2019
Mucormycosis is an emerging life-threatening fungal infection caused by Mucorales. This infection occurs mainly in immunocompromised patients, especially with hematological malignancy, transplantation, or diabetes mellitus.
, Fanny Lanternier, François Danion
exaly   +3 more sources

Global Epidemiology of Mucormycosis

open access: yesJournal of Fungi (Basel, Switzerland), 2019
Mucormycosis is an angio-invasive fungal infection, associated with high morbidity and mortality. A change in the epidemiology of mucormycosis has been observed in recent years with the rise in incidence, new causative agents and susceptible population ...
Arunaloke Chakrabarti   +2 more
exaly   +3 more sources

Prevalence, predictors and outcome of pulmonary mucormycosis in COVID-19 associated rhino orbital mucormycosis in a tertiary care centre in south India [PDF]

open access: yesCurrent Medical Mycology, 2023
Background and Purpose: India witnessed an explosive rise in mucormycosis following COVID-19 infection. While rhino orbital mucormycosis was the most common presentation, pulmonary mucormycosis was closely followed.
Karthigeyan Thanjavur Sethuraman   +3 more
doaj   +1 more source

Rise of Mucormycosis during the COVID-19 Pandemic and the Challenges Faced [PDF]

open access: yesCurrent Medical Mycology, 2023
Mucormycosis (previously called zygomycosis) is a diverse group of increasingly recognized and frequently fatal mycotic diseases caused by members of the class zygomycetes. Mucormycosis is around 80 times more common in India, compared to other developed
Malavika Kottarathil   +3 more
doaj   +1 more source

Mucormycosis and COVID-19: A systemic review

open access: yesMedical Journal of Dr. D.Y. Patil Vidyapeeth, 2022
COVID-19 presents severely in persons with immunocompromised states such as diabetes mellitus. Steroids are used in the management of COVID-19.
Ankit Kaushik   +3 more
doaj   +1 more source

A rare case of post-COVID mucormycosis of the kidney

open access: yesCurrent Medicine Research and Practice, 2022
Post-COVID mucormycosis of the kidney is a rare phenomenon with only very few cases reported, worldwide. Among the various opportunistic fungal infections, mucormycosis is associated with the highest mortality.
Ankit Tyagi   +3 more
doaj   +1 more source

COVID-19 associated mucormycosis in Assiut University Hospitals: a multidisciplinary dilemma

open access: yesScientific Reports, 2022
Mucormycosis is a life-threatening opportunistic angioinvasive fungal infection. We aimed to describe the frequency, presentations, predictors, and in-hospital outcome of mucormycosis patients in the scope of CoronaVirusDisease-19 (COVID-19) during the ...
Sahar Farghly Youssif   +12 more
doaj   +1 more source

Crush cytology smears – A novel approach to rapid diagnosis of rhino-orbital mucormycosis in post-COVID-19 patients: A single-center study

open access: yesAsian Journal of Medical Sciences, 2022
Background: With recent surge in SARS-COVID-19, cases of rhinocerebral mucormycosis are on rise. Rapid diagnosis of mucormycosis is essential as delay in the treatment is associated with dreadful outcome.
Amruta Patil   +3 more
doaj   +1 more source

Rhino-orbital Mucormycosis in a COVID-19 Patient: The First Case in Malaysia

open access: yesProceedings of Singapore Healthcare, 2022
Mucormycosis is an aggressive and potentially fatal fungal infection caused by fungi of the order Mucorales. There has been an increase in the number of cases of rhino-orbital mucormycosis in people with COVID-19, particularly in India.
Chee Yik Chang   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy